{
  "id": 15605204,
  "title": "H.C. Wainwright raises Enliven Therapeutics price target to $73",
  "url": "https://urgent.news/2026/10/19/h-c-wainwright-raises-enliven-therapeutics-price-target-to-73",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-19T12:56:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-raises-enliven-therapeutics-price-target-to-73-93CH-4957473"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has increased its price target for Enliven Therapeutics (NASDAQ: ELVN) to $73 from the previous $65 level, retaining a Buy rating. This new target aligns with the overall analyst consensus, which is Strong Buy, with price targets ranging between $64 and $82. The stock is currently trading at $37.32, having experienced an 8.6% decline over the past week despite a remarkable 142% increase year-to-date. H.C. Wainwright highlighted the company's agreement with the FDA on the design of the upcoming randomized Phase 3 ENABLE-2 trial, which is scheduled to commence by the end of 2026. The trial aims to compare relcobatinib (ELVN-001) at an 80mg once-daily dose versus an investigator-selected second-generation TKI in patients with second-line or later chronic myeloid leukemia. Approximately 450 participants will be randomly assigned to the two treatment groups, with the primary endpoint being a major molecular response at Week 24, and the key secondary endpoint being a major molecular response at Week 96. Based on the positive results from the Phase 1 ENABLE trial in second-line or later chronic myeloid leukemia patients, where relcobatinib at 80mg resulted in a 61% overall major molecular response by 24 weeks, H.C. Wainwright sees a high probability of a favorable outcome in the ENABLE-2 trial. The firm has also lowered its projected discount rate to 10% from 11% and adjusted its discounted cash flow (DCF) valuation accordingly. According to InvestingPro analysis, the stock currently appears overvalued relative to its estimated fair value. Investors can access seven additional InvestingPro Tips for further insights into ELVN's financial health and growth prospects.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}